Emerging drugs in chronic obstructive pulmonary disease

Expert Opinion on Emerging Drugs

Volumn 14, Issue 1, 2009, Pages 181-194

  Seifart, Carola ^a   Vogelmeier, Claus ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Bronchodilator; COPD; COPD therapy; Drug development; LABA; LAMA

Indexed keywords

ACLIDINIUM BROMIDE; AMFEBUTAMONE; ANTIINFLAMMATORY AGENT; AS 111793; AZD 8309; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CARMOTEROL; CHF 5407; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DAROTROPIUM BROMIDE; FLUTICASONE; FORMOTEROL; GLYCOPYRRONIUM BROMIDE; GSK 656398; GSK 856333; GW 642444; INDACATEROL; IPRATROPIUM BROMIDE; LAS 35201; MILVETEROL; NICOTINE QBETA; NICOTINE VACCINE; ORM3; PHOSPHODIESTERASE IV INHIBITOR; PROTEINASE; PROTEINASE INHIBITOR; QAT 370; QVA 149; SALBUTAMOL; SALMETEROL; SB 681323; SCH 527123; TA NIC; TD 5742; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARENICLINE; ZD 0892; GLUCOCORTICOID;

AIRWAY OBSTRUCTION; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONSTIPATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DYSPNEA; EXERCISE; FORCED EXPIRATORY VOLUME; HEADACHE; HEART DEATH; HEART INFARCTION; HUMAN; INCIDENCE; INFLAMMATION; LUNG PARENCHYMA; MORBIDITY; MORTALITY; NAUSEA; NONHUMAN; PATIENT COMPLIANCE; REVIEW; SINGLE DRUG DOSE; SMOKING; SMOKING CESSATION; STROKE; TISSUE REGENERATION; URINE RETENTION; VOMITING; XEROSTOMIA; ANIMAL; DRUG COMBINATION; DRUG DELIVERY SYSTEM; PATHOPHYSIOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BRONCHODILATOR AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; MEDICATION ADHERENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING CESSATION;

EID: 65649094413     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728210902798055     Document Type: Review

References (129)

1. Halbert RJ, Natoli JL, Gano A, et al. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006;28(3):523-532 (Pubitemid 44794666)
2. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007;370(9589):741-750 (Pubitemid 47321907)
3. Lokke A, Lange P, Scharling H, et al. Developing COPD: a 25 year follow up study of the general population. Thorax 2006;61(11):935-939 (Pubitemid 44787161)
4. Liu S, Zhou Y, Wang X, et al. Biomass fuels are the probable risk factor for chronic obstructive pulmonary disease in rural South China. Thorax 2007;62(10):889-897 (Pubitemid 47598354)
5. Blanc PD, Iribarren C, Trupin L, et al. Occupational exposures and the risk of COPD: dusty trades revisited. Thorax 2009;64(1):6-12
6. Anzueto A, Tashkin D, Menjoge S, Kesten S. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm Pharmacol Ther 2005;18(2):75-81 (Pubitemid 40092656)
7. Donaldson GC, Wedzicha JA. COPD exacerbations. 1: Epidemiology. Thorax 2006;61(2):164-168
8. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008;178(4):332-338
9. Anthonisen NR, Connett JE, Murray RP, et al. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002;166(5):675-679 • Interventional trail that shows impressively the impact of smoking and smoking cessation on lung function course over more than a decade. (Pubitemid 34971849)
10. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176(6):532-555 •• Actual report of the Global Initiative for Chronic Obstructive Lung Disease (GOLD). The first step in the GOLD program was to prepare a consensus report, Global Strategy for the Diagnosis, Management and Prevention of COPD, published in 2001. The present, newly revised document follows the same format as the original consensus report, but has been updated to reflect the many publications on COPD that have appeared. (Pubitemid 47403272)
11. Casaburi R, Porszasz J. Reduction of hyperinflation by pharmacologic and other interventions. Proc Am Thorac Soc 2006;3(2):185-189
12. Ferguson GT. Why does the lung hyperinflate? Proc Am Thorac Soc 2006;3(2):176-179
13. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23(6):932-946 (Pubitemid 38807371)
14. Casaburi R, Kukafka D, Cooper CB, et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005;127(3):809-817 (Pubitemid 40775509)
15. O'Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004;23(6):832-840 (Pubitemid 38807355)
16. Rennard SI, Anderson W, ZuWallack R, et al. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163(5):1087-1092 (Pubitemid 32378441)
17. O'Donnell DE, Voduc N, Fitzpatrick M, Webb KA. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 2004;24(1):86-94 (Pubitemid 39029073)
18. Salpeter SR, Buckley NS. Systematic review of clinical outcomes in chronic obstructive pulmonary disease: beta-agonist use compared with anticholinergics and inhaled corticosteroids. Clin Rev Allergy Immunol 2006;31(2-3):219-230 (Pubitemid 44804950)
19. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Jama 2008;300(12):1439-1450
20. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359(15):1543-54 •• Report of a 4-year period of the UPLIFT study: In patients with COPD, therapy with tiotropium was associated with improvements in lung function, quality of life and exacerbations but did not significantly reduce the rate of decline in FEV(1).
21. van Noord JA, Aumann JL, Janssens E, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006;129(3):509-517
22. Vogelmeier C, Kardos P, Harari S, et al. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med 2008; 102(11):1511-1520
23. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320(7245):1297-303 • The ISOLDE trail: Fluticasone propionate 500 μg twice daily did not affect the rate of decline in FEV(1) but did produce a small increase in FEV(1). Patients on fluticasone propionate had fewer exacerbations and a slower decline in health status. These improvements in clinical outcomes support the use of this treatment in patients with moderate to severe chronic obstructive pulmonary disease. (Pubitemid 30245717)
24. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356(8):775-789 •• The TORCH study: A randomized, double-blind trial comparing salmeterol at a dose of 50 μg plus fluticasone propionate at a dose of 500 μg twice daily (combination regimen), administered with a single inhaler, with placebo, salmeterol alone or fluticasone propionate alone for a period of 3 years. The reduction in death from all causes among patients with COPD in the combination-therapy group did not reach the predetermined level of statistical significance. There were significant benefits in all other outcomes among these patients. (Pubitemid 46294610)
25. Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005;352(19):1967-1976 •• Interesting study that shows the decrease of histone deacetylase activity in patients with COPD and offers an explanation of the steroid resistance in COPD.
26. Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175(2):144-149 • This study demonstrates that combination therapy with salmeterol/fluticasone compared with salmeterol monotherapy significantly reduces the frequency of moderate/severe exacerbations in patients with severe COPD.
27. Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177(1):19-26
28. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350(10):1005-1012 (Pubitemid 38269277)
29. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31(2):416-469
30. Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J 2008;31(4):869-873 • This study is a 3-year longitudinal study called Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) that identifies parameters that predict disease progression and examines biomarkers that correlate with COPD subtypes and may predict disease progression.
31. Massaro GD, Massaro D. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nat Med 1997;3(6):675-677 •• The Massaro study opened the discussion of structural regeneration in emphysema. (Pubitemid 27264979)
32. March TH, Cossey PY, Esparza DC, et al. Inhalation administration of all-trans-retinoic acid for treatment of elastase-induced pulmonary emphysema in Fischer 344 rats. Exp Lung Res 2004;30(5):383-404 (Pubitemid 38925125)
33. March TH, Bowen LE, Finch GL, et al. Effects of strain and treatment with inhaled aII-trans-retinoic acid on cigarette smoke-induced pulmonary emphysema in mice. Copd 2005;2(3):289-302 (Pubitemid 43879445)
34. Fujita M, Ye Q, Ouchi H, et al. Retinoic acid fails to reverse emphysema in adult mouse models. Thorax 2004;59(3):224-230 (Pubitemid 38339879)
35. Lucey EC, Goldstein RH, Breuer R, et al. Retinoic acid does not affect alveolar septation in adult FVB mice with elastase-induced emphysema. Respiration 2003;70(2):200-205 (Pubitemid 36578790)
36. Connors AF Jr, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996;154(4 Pt 1):959-967 • The study analyzes the outcomes of patients hospitalized with an acute exacerbation of severe chronic obstructive pulmonary disease (COPD) and determines the relationship between patient characteristics and length of survival.
37. Ai-Ping C, Lee KH, Lim TK. In-hospital and 5-year mortality of patients treated in the ICU for acute exacerbation of COPD: a retrospective study. Chest 2005;128(2):518-524 • This is a retrospective cohort study that examines both the in-hospital and 5-year mortality rates of patients with COPD exacerbations and identifies the clinical predictors of these outcomes. (Pubitemid 41140475)
38. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994;272(19):1497-1505 (Pubitemid 24986688)
39. Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001;163(5):1256-1276 (Pubitemid 32378468)
40. Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005;142(4):233-239 (Pubitemid 40216240)
41. Fiore M, Bailey W, Cohen S, et al. Treating tobacco use and dependence. Clinical practice guideline. Rockville MD: US department of health and human services, public health service 2000
42. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999;340(9):685-691 (Pubitemid 29110752)
43. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006;296(1):47-55
44. Hieda Y, Keyler DE, Vandevoort JT, et al. Active immunization alters the plasma nicotine concentration in rats. J Pharmacol Exp Ther 1997;283(3):1076- 1081 (Pubitemid 28016479)
45. Pentel PR, Malin DH, Ennifar S, et al. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav 2000;65(1):191-198 (Pubitemid 30018012)
46. Maurer P, Bachmann MF. Vaccination against nicotine: an emerging therapy for tobacco dependence. Expert Opin Investig Drugs 2007;16(11):1775-1783 (Pubitemid 350187391)
47. Cornuz J, Zwahlen S, Jungi WF, et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS ONE 2008;3(6): e2547
48. Roiko SA, Harris AC, Keyler DE, et al. Combined active and passive immunization enhances the efficacy of immunotherapy against nicotine in rats. J Pharmacol Exp Ther 2008;325(3):985-993 (Pubitemid 351724343)
49. Hanania NA, Kalberg C, Yates J, et al. The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD. Pulm Pharmacol Ther 2005;18(1):19-22 (Pubitemid 39647749)
50. Koumis T, Samuel S. Tiotropium bromide: a new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease. Clin Ther 2005;27(4):377-392 (Pubitemid 40732646)
51. Kikkawa H, Naito K, Ikezawa K. Tracheal relaxing effects and beta 2-selectivity of TA-2005, a newly developed bronchodilating agent, in isolated guinea pig tissues. Jpn J Pharmacol 1991;57(2):175-185
52. Voss HP, Donnell D, Bast A. A typical molecular pharmacology of a new long-acting beta 2-adrenoceptor agonist, TA 2005. Eur J Pharmacol 1992;227(4):403-409
53. Kikkawa H, Kanno K, Ikezawa K. TA-2005, a novel, long-acting, and selective beta 2-adrenoceptor agonist: characterization of its in vivo bronchodilating action in guinea pigs and cats in comparison with other beta 2-agonists. Biol Pharm Bull 1994;17(8):1047-1052 (Pubitemid 24276338)
54. Haeussermann S, Acerbi A, Brand P, et al. Lung deposition of carmoterol in healthy subjects, patients with asthma and patients with COPD. Eur Respir J 2006;28:211s
55. Acerbi D, Brambilla G, Kottakis I. Advances in asthma and COPD management: delivering CFC-free inhaled therapy using Modulite technology. Pulm Pharmacol Ther 2007;20(3):290-303 (Pubitemid 46242202)
56. Nandeuil A, Kottakis I, Raptis H, et al. Safety and tolerability of the novel very long acting β2-agonist carmoterol given as a 2μg qd dose; 8days comparison with formoterol and placebo in patients with persistent asthma. Eur Respir J 2006;28:665s
57. Kottakis I, Nandeuil A, Raptis H, et al. Efficacy of the novel very long-acting β2-agonist carmoterol following 7 days once daily dosing: comparison with twice daily formoterol in patient with persistent asthma. Eur Respir J 2006;28:665s
58. Battram C, Charlton SJ, Cuenoud B, et al. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethylindan-2-ylamino)-1- hydroxy-ethyl]-8- hydroxy-1H-quino lin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther 2006;317(2):762-770
59. Beeh KM, Derom E, Kanniess F, et al. Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma. Eur Respir J 2007;29(5):871-878 (Pubitemid 46711890)
60. Brookman LJ, Knowles LJ, Barbier M, et al. Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma. Curr Med Res Opin 2007;23(12):3113-3122
61. LaForce C, Alexander M, Deckelmann R, et al. Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: a 7-day dose-ranging study. Allergy 2008;63(1):103-111 (Pubitemid 350198242)
62. Aubier M, Duval X, Knight H, et al. Indacaterol, a novel once-daily β2-agonist, is effective and well tolerated on multiple dosing in patients with mild-to-moderate COPD. Eur Respir J 2005;26:287s
63. Rennard S, Bantje T, Centanni S, et al. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med 2008;102(7):1033-1044
64. Beier J, Chanez P, Martinot J, et al. Safety, tolerability and efficacy of indacaterol, a novel once daily β2-agonist, in patients with CPD: a 28-day randomized, placebo controlled clinical trail. Pulm Pharmacol Ther 2007;(20):740-749 (Pubitemid 47446351)
65. Cazzola M, Matera MG, Lotvall J. Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2005;14(7):775-783 (Pubitemid 41030946)
66. Cazzola M, Matera MG. Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol 2008;155(3):291-299
67. Miralpeix M, Gavalda A, Morcillo E, et al. Assesement of the potency and duration of action of aclidinium bromide in guinea pig isolated trachea in vitro. Eur Respir J 2007;30:359s
68. Gavalda A, Miralpeix M, Ramos I, et al. Aclidinium bromide, a novel muscarinic receptor antagonist combining long residence at M3 receptors and rapid plasma clearance. Eur Respir J 2007;30:209s
69. Joos G, Schelfhout V, Kanniess F, et al. Bronchodilator effects of aclidinium bromide, a novel long-acting cholinergic, in COPD patients: a phase II study. Eur Respir J 2007;30:210s
70. Schelfhout V, Joos G, Garcia GIL, et al. Bronchodilator/bronchoprotective effects of aclidinium bromide, a novel long-acting anticholinergic: a phase I study. Eur Respir J 2007;30:356s
71. Thomas R, Eltringham E, Tansley R, Snape S. Low systemic exposure of NVA 237, a once daily antimuscarinic bronchodilator, in healthy human volunteers. Proc Am Thorac Soc 2006;3:A725
72. Cooper C, Walker I, Knowles I. NVA237 and tiotropium bromide demonstrate similar efficacy in an anesthetized rabbit model of metacholine induced bronchoconstriction. Proc Am Thorac Soc 2006;3:A117
73. Kuna P, Vinkler I, Overend T, et al. Efficacy and tolerability of NVA 237, a once daily long acting muscarinic antagonist, in COPD patients. Eur Respir J 2007;30:354s
74. Singh D, Corris P, Snape S. NVA237, a once-daily inhaled antimuscarinic, provides 24-hour bronchodilator efficacy in patients with moderate-to-severe COPD. Proc Am Thorac Soc 2006;3:A113
75. Gunawardena K, Wild R, Kirkpatrick J, Snape S. NVA 237, a once daily antimuscarinic, demonstrates sustained bronchodilation and is well tolerated in patients with reversible obstructive airway disease. Proc Am Thorac Soc 2006;3:A117
76. Lu S, Parekh D, Kuznetsowa O, et al. An oral selective M3 anticholinergic receptor antagonist in COPD. Eur Respir J 2006;28:772-780 (Pubitemid 46331998)
77. Patacchini R, Bergamaschi M, Harrison S, et al. In vitro pharmacological profile of CHF 5407, a potent, long acting and selective muscarinic M3 receptor antagonist. Eur Respir J 2007;30:25s
78. Villetti G, Bassani F, Bergamaschi M, et al. In vivo potent and long-lasting bronchodilator activity of muscarinic M3 receptor antagonist CHF5407. Eur Respir J 2007;30:26s
79. Tashkin D, Littner M, Andrews C, et al. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir Med 2008;102(4):479-487
80. Vogelmeier C, Harari S, Fonay K, et al. Formoterol and tiotropium both improve lung function in stable COPD patients, with some additional benefit when given together. Eur Respir J 2006;28:429s
81. Rabe KF, Timmer W, Sagkriotis A, Viel K. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 2008;134(2):255-262
82. Arievich H, Potena A, Fonay K, et al. Formoterol given eitehr alone or together with tiotropium, reduces the rates of exacerbations in stable COPD patients. Eur Respir J 2006;28:287s
83. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007;146(8):545-555 (Pubitemid 351650535)
84. Cazzola M, Matera MG. The effective treatment of COPD: anticholinergics and what else? Drug Discov Today 2006;3:277-286
85. Rossoni G, Manfredi B, Razzetti R, et al. Positive interaction of the novel beta2-agonist carmoterol and tiotropium bromide in the control of airway changes induced by different challenges in guinea-pigs. Pulm Pharmacol Ther 2007;20(3):250-257 (Pubitemid 46240951)
86. Fitzgerald MF, Fox JC. Emerging trends in the therapy of COPD: bronchodilators as mono- and combination therapies. Drug Discov Today 2007;12(11-12):472-478 (Pubitemid 46795590)
87. Saetta M, Turato G, Maestrelli P, et al. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163(6):1304-1309 (Pubitemid 32506590)
88. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350(26):2645-2653 (Pubitemid 38787999)
89. Majo J, Ghezzo H, Cosio MG. Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur Respir J 2001;17(5):946-953 (Pubitemid 32600344)
90. Keddissi JI, Younis WG, Chbeir EA, et al. The use of statins and lung function in current and former smokers. Chest 2007;132(6):1764-1771
91. Mancini GB, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006;47(12):2554-2560 (Pubitemid 43866389)
92. Soyseth V, Brekke P, Smith P, Omland T. Statin use is associated with reduced mortality in chronic obstructive pulmonary disease. Eur Respir J 2006;(29):279-283
93. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005;45:89-118 (Pubitemid 40261799)
94. Hothersall E, McSharry C, Thomson NC. Potential therapeutic role for statins in respiratory disease. Thorax 2006;61(8):729-734 (Pubitemid 44211783)
95. Dandona P, Dhindsa S, Ghanim H, Chaudhuri A. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens 2007;21(1):20-27 (Pubitemid 44921816)
96. Fan Chung K. Phosphodiesterase inhibitors in airways disease. Eur J Pharmacol 2006;533(1-3):110-117 (Pubitemid 43348344)
97. Barber R, Baillie GS, Bergmann R, et al. Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. Am J Physiol Lung Cell Mol Physiol 2004;287(2): L332-43 (Pubitemid 38943915)
98. Martorana PA, Beume R, Lucattelli M, et al. Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med 2005;172(7):848-853 (Pubitemid 41369068)
99. Peter D, Jin SL, Conti M, et al. Differential expression and function of phosphodiesterase 4(PDE4) subtypes in human primary CD4+ T cells: predominant role of PDE4D. J Immunol 2007;178(8):4820-4831 (Pubitemid 46595264)
100. Gamble E, Grootendorst D, Brightling C, et al. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;168:976-982 (Pubitemid 37267176)
101. Rennard SI, Schachter N, Strek M, et al. Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest 2006;129(1):56-66 (Pubitemid 43265243)
102. Grootendorst DC, Gauw SA, Verhoosel RM, et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007;62(12):1081-1087 (Pubitemid 350206202)
103. Calverley P, Sanchez-Toril F, McIvor A, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:154-161 (Pubitemid 47057851)
104. Rabe K, Bateman E, O'Donnell D, et al. Roflumilast-an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005;366(9485):563-571 (Pubitemid 41140331)
105. Spina D. Phosphodiesterase 4 inhibitors: current status. Br J Pharmacol 2008;(155):308-315
106. Smith S, Cieslinski L, Newton R, et al. Discovery of BRL 50481, a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages and CD8+ T-lymphocytes. Mol Pharmacol 2004;66:1679-1689
107. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000;55(2):114-120 (Pubitemid 30245950)
108. Franciosi LG, Page CP, Celli BR, et al. Markers of disease severity in chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2006;19(3):189-199
109. Mahler DA, Huang S, Tabrizi M, Bell GM. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest 2004;126(3):926-934 (Pubitemid 39258050)
110. O'Connor B, Leaker B, Barnes P, et al. Inhibition of LPS-induced neutrophilic inflammation in healthy volunteers. Eur Respir J 2007;30(Suppl 51):1294
111. Costa C, Rufino R, Traves SL, et al. CXCR3 and CCR5 chemokines in induced sputum from patients with COPD. Chest 2008;133(1):26-33
112. Birrell MA, Wong S, Hardaker EL, et al. IkappaB kinase-2-independent and -dependent inflammation in airway disease models: relevance of IKK-2 inhibition to the clinic. Mol Pharmacol 2006;69(6):1791-1800 (Pubitemid 43894295)
113. Tudhope SJ, Catley MC, Fenwick PS, et al. The role of IkappaB kinase 2, but not activation of NF-kappaB, in the release of CXCR3 ligands from IFN-gamma-stimulated human bronchial epithelial cells. J Immunol 2007;179(9):6237-6245
114. Renda T, Baraldo S, Pelaia G, et al. Increased activation of p38 MAPK in COPD. Eur Respir J 2008;31(1):62-69
115. Smith SJ, Fenwick PS, Nicholson AG, et al. Inhibitory effect of p38 mitogen-activated protein kinase inhibitors on cytokine release from human macrophages. Br J Pharmacol 2006;149(4):393-404 (Pubitemid 44582246)
116. Beisswenger C, Platz J, Seifart C, et al. Exposure of differentiated airway epithelial cells to volatile smoke in vitro. Respiration 2004;71(4):402-409 (Pubitemid 39179178)
117. Zu YL, Qi J, Gilchrist A, et al. p38 mitogen-activated protein kinase activation is required for human neutrophil function triggered by TNF-alpha or FMLP stimulation. J Immunol 1998;160(4):1982-1989 (Pubitemid 28106489)
118. Medicherla S, Fitzgerald MF, Spicer D, et al. p38alpha-selective mitogen-activated protein kinase inhibitor SD-282 reduces inflammation in a subchronic model of tobacco smoke-induced airway inflammation. J Pharmacol Exp Ther 2008;324(3):921-929
119. Black P, Staykova T, Chacko E, et al. Prophylactic antibiotic therapy for chronic bronchitis. Cochrane Database Syst Rev 2003;(1):CD004105
120. Seemungal TA, Wilkinson TM, Hurst JR, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008;178(11):1139-1147
121. Kunisaki KM, Niewoehner DE. Antibiotic prophylaxis for chronic obstructive pulmonary disease: resurrecting an old idea. Am J Respir Crit Care Med 2008;178(11):1098-1099
122. Sethi S, the PULSE study group. Determinants of exacerbation frequency in the PULSE study. Am J Respir Crit Care Med 2008;177:A140
123. Churg A, Wang R, Wang X, et al. Effect of an MMP-9/MMP-12 inhibitor on smoke-induced emphysema and airway remodelling in guinea pigs. Thorax 2007;62(8):706-713 (Pubitemid 47235016)
124. Barnes PJ. Frontrunners in novel pharmacotherapy of COPD. Curr Opin Pharmacol 2008;8(3):300-307
125. Pemberton P, Kobayashi D, Wilk B, et al. Inhaled recombinant 1-antitrypsin ameliorates cigarette smoke-induced emphysema in the mouse. COPD 2006;3:101-108 (Pubitemid 43739182)
126. Belloni PN, Garvin L, Mao CP, et al. Effects of all-trans-retinoic acid in promoting alveolar repair. Chest 2000;117(5 Suppl 1):235S-41S (Pubitemid 30326965)
127. Roth MD, Connett JE, D'Armiento JM, et al. Feasibility of retinoids for the treatment of emphysema study. Chest 2006;130(5):1334-1345 (Pubitemid 44786724)
128. Wang D, Haviland DL, Burns AR, et al. A pure population of lung alveolar epithelial type II cells derived from human embryonic stem cells. Proc Natl Acad Sci USA 2007;104(11):4449-4454 (Pubitemid 47186246)
129. Vestbo J, Anderson J, Willits J, et al. The towards a revolution in COPD health (TORCH) study: the effects of compliance on mortality over 3 years. Am J Respir Crit Care Med 2008;177:A962 • A subanalysis of the TORCH trial show that patients with good compliance have a better prognosis independent of the drugs they receive.